impact of new tkis on nsclc treatment planning
Published 5 years ago • 56 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
3:28
the future of nsclc treatment
-
2:03
tkis to treat egfrm-positive nsclc
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
1:13
guiding nsclc treatment with biomarkers
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
4:12
ideal treatment duration of tyrosine kinase inhibitors in egfr-mutant nsclc
-
1:41
recent developments in the treatment of nsclc
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
6:15
the clinical use of tyrosine kinase inhibitors in egfr-mutant nsclc
-
1:13
the impact of p53 mutation on survival in egfr-mutated nsclc patients
-
1:32
what is the best sequence of treatment for nsclc?
-
1:40
maximizing treatment benefits in nsclc
-
4:37
advances in efgr-mutant nsclc treatment
-
2:21
current treatment options for nsclc without driver mutations
-
1:16
the future of trk inhibitors in lung cancer treatment
-
2:10
novel therapies for the treatment of nsclc: immunotherapy and targeted agents
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
1:33
dr. anne chiang on molecular testing in lung cancer treatment planning
-
6:55
the prognostic value of ctdna in nsclc treated with neoadjuvant chemoimmunotherapy